Clinical Trials
3 trialsNCT07089992 2026-05-14
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed